Skip to main content

Table 4 Results for all participants recruited during the pollen season

From: Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study

  Treatment days No treatment days P value*
FF MPAzeFlu MF OAH mono
N users Day 1 331 (5.5%) 159 (2.7%) 351 (5.9%) 1414 (23.6%) 3736 (62.4%)  
Symptoms Day 1
 Runny nose (%) 69 74 75 78 69 0.77
 Itchy nose (%) 68 55 65 67 57 0.006
 Sneezing (%) 79 73 76 87 77 0.20
 Nasal congestion (%) 75 74 79 71 64 0.37
 Red eyes (%) 50 44 42 52 42 0.56
 Itchy eyes (%) 70 64 68 74 64 0.22
 Watery eyes (%) 48 42 45 54 43 0.29
Impact of symptoms Day 1
 Sleep (%) 44 44 47 41 32 0.70
 Daily activities (%) 41 50 50 49 41 0.36
 Work/school (%) 31 42 33 33 27 0.02
 Bothersome (%) 76 77 77 78 74 0.94
ARIA score (%)
 0 11 11 12 11 16  
 1 29 26 23 28 32  
 2 30 24 27 26 24 0.08
 3 19 16 23 21 16  
 4 12 23 16 15 12  
 Median [p25-75] 2 [1–3] 2 [1–3] 2 [1–3] 2 [1–3] 2 [1–3] 0.36
VAS global Day 1 (%)
 N 331 159 351 1414 3736  
 <20 17 18 16 16 30 0.53
 20-49 32 28 33 26 28  
 ≥50 51 55 51 58 42  
 Median [p25-75] 50 [28–71] 52 [25–73] 50 [28–68] 55 [30–75] 40 [15–66] 0.72
VAS global – all days (%)
 N days 3186 2594 4093 9780 23,377  
 N users 507 256 548 2196 4569  
 Average number of days per user± 6.3 10.1 7.5 4.5 5.1  
 <20 42 55 52 48 58 0.0001
 20-49 32 27 30 28 24  
 ≥50 26 18 18 24 18  
 Median [p25-75] 26 [8–50] 16 [6–38] 19 [7–39] 21 [7–48] 14 [3–38] 0.0001
  1. FF Fluticasone Furoate, MF Mometasone Furoate, MPAzeFlu Azelastine-Fluticasone Propionate
  2. * Comparing MPAzeFlu versus FF or MF. Chi square tests were used for categorical variables (i.e. symptoms and impact of symptoms, ARIA score, global VAS categories); Kruskal–Wallis tests were used for continuous variables (i.e. ARIA score, global VAS)
  3. ±Estimated by dividing the total number of days for which the use of a medication was reported by the total number of users reporting that medication
  4. p25: 25th percentile; p75: 75th percentile
\